Alphamab Oncology has announced research updates for their drug JSKN003, which were presented at the 2025 ASCO Annual Meeting held from May 30 to June 3. The updates are based on findings from two clinical studies, JSKN003-101 and JSKN003-102. JSKN003-101 is a first-in-human, open-label, multi-center phase I clinical study conducted in Australia, focusing on patients with advanced or metastatic solid tumors. Meanwhile, JSKN003-102 is a phase I/II clinical study carried out in China, targeting patients with advanced solid tumors. These studies evaluate the efficacy and safety of JSKN003 for various indications. Alphamab Oncology emphasizes its proprietary protein engineering platforms and aims to develop multifunctional biological drug candidates to benefit patients globally. However, the company advises cautious handling of its shares, as successful development and marketing of JSKN003 are not guaranteed.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.